Kidney Cancer

Real-world data demonstrated that knowing a patient’s stage and subtype of renal cell carcinoma, a type of kidney cancer, may provide cancer teams with the information needed to determine potential prognosis and recurrence risk.

Patients with clear cell renal cell carcinoma had improved overall survival when treated with adjuvant Keytruda compared to placebo.

Opdivo failed to improve disease-free survival in patients with localized renal cell carcinoma at high risk of relapse, according to findings from CheckMate 914.

After cancer, taking baby steps towards stuff you want to do is what matters.

Some with metastatic cancers receiving end-of-life-initiated immunotherapy may have a decreased risk of mortality when treated at a high-volume facility, research found.

Recently, I have been focusing on the concept of Mattering, and it has boosted my mental health.

We all know that stress is bad.

Treatment with Welireg — now approved by the FDA — helped shrink and stabilize tumors from metastatic renal cell carcinoma with minimal side effects, a patient told CURE®.

The Food and Drug Administration has approved Welireg for patients with advanced renal cell carcinoma, a type of kidney cancer, following treatment with a PD-1 or PD-L1 inhibitor and a VEGF-TKI.

I have cancer and don't believe in god, can I still be spiritual?

The Welireg-Cabometyx treatment combination demonstrated anti-tumor activity for some patients with clear cell renal carcinoma, according to a phase 2 trial.

Patients with advanced clear cell renal cell carcinoma treated with zanzalintinib had experienced promising antitumor activity with manageable toxicity regardless of prior treatment with cabozantinib.

Researchers continue to investigate novel immunotherapy drugs for the treatment of renal cell carcinoma.

Although research has delved into the potential link between clonal hematopoiesis and heart-related events such as heart attacks and strokes in patients with kidney cancer, more research is needed to further understand this association.

Circulating tumor DNA — which is observed via blood test — may be helpful in determining which patients with kidney cancer need more intense treatment and who can have their therapies deescalated.

While translocation renal cell carcinoma tends to respond well to immunotherapy, there is still a need for more investigation into targeted therapies for this patient population.

Welireg led to improved time to progression and objective response rates compared to Afinitor for patients with advanced clear cell renal cell carcinoma, according to study findings.

Patients with intermediate- or poor-risk clear-cell metastatic renal cell carcinoma saw improved response rates with Opdivo with or without Yervoy.

From Julia Louis-Dreyfus opening up about her breast cancer experience to Dolph Lundgren discussing his experience, here’s what’s happening in the cancer space this week.

The FDA granted Welireg a priority review after it showed promising outcomes for patients with pretreated advanced renal cell carcinoma.

Treatment with Welireg significantly improved progression-free survival rates in patients with advanced renal cell carcinoma, the most common type of kidney cancer.

From Jill Martin revealing an updated about her cancer to Casey DeSantis announcing breast cancer diagnosis, this is what’s happening in the oncology space this week.

Patients with metastatic clear cell renal cell carcinoma who received corticosteroids during Opdivo treatment did not experience a negative impact on survival.

Even with the increase of immunotherapy utilization to treat patients with advanced renal cell carcinoma, more research is needed to determine in which order to administer it as later lines of therapy.

An expert explained what aspects of a patient’s disease cancer care teams use to determine the best treatment options for patients with clear cell renal cell carcinoma.

Patients with BAP1-mutated renal cell carcinoma who were treated with Lynparza obtained responses with favorable side effect profiles.

A randomized clinical trial, CHEERS, determined that the combination of stereotactic body radiotherapy (SBRT) and immune checkpoint inhibitors (ICIs) were ineffective as treatment for patients with advanced solid tumors.

Adolescents and young adults undergoing VEGF treatment for nonmetastatic, high-risk renal cell carcinoma may still experience heart-related conditions like left ventricular systolic dysfunction and high blood pressure.

The addition of Tecentriq to Cabometyx did not improve the length of time patients lived without their disease getting worse for individuals with previously treated advanced kidney cancer, and came with additional side effects, too, recent research showed.